Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome.

Authors:
Eirini Mavropoulou
Eirini Mavropoulou
University Medical Center Goettingen
Göttingen | Germany
Kristin Ternes
Kristin Ternes
Universitatsklinikum Gottingen
Steffen Kunsch
Steffen Kunsch
University of Ulm
Germany
Volker Ellenrieder
Volker Ellenrieder
University Medical Center Goettingen
Germany
Albrecht Neesse
Albrecht Neesse
Philipps University Marburg
United Kingdom
Ahmad Amanzada
Ahmad Amanzada
University Medical Center
Germany

BMJ Open Gastroenterol 2019 27;6(1):e000258. Epub 2019 Feb 27.

Department of Gastroenterology and Gastrointestinal Oncology, Universitatsklinikum Gottingen, Gottingen, Germany.

Background: Concurrent cytomegalovirus (CMV) colitis in inflammatory bowel disease (IBD) and after haematopoietic stem cell transplantation (HSCT) is an important clinical entity associated with high rates of morbidity and mortality.

Methods: A retrospective study of 47 patients with IBD and 61 HSCT patients was performed regarding the evaluation of diagnostic accuracy of applied methods, predictors, risk factors for CMV disease manifestation, the proportion of patients with antiviral treatment and disease outcome.

Results: The sensitivity of quantitative PCR (qPCR) with a cut-off value of >250 copies/mg for CMV colitis in patients with IBD and HSCT patients was 79% and 92%, respectively. Predictors for CMV colitis in the IBD cohort were anaemia and the presence of endoscopic ulcers. Glucocorticoids, calcineurin inhibitors and >2 concurrent lines of treatment with immunosuppressive drugs could be identified as risk factors for CMV colitis in the IBD cohort with an OR of 7.1 (95% CI 1.7 to 29.9), 21.3 (95% CI 2.4 to 188.7) and 13.4 (95% CI 3.2 to 56.1), respectively. Predictors and risk factors for CMV gastroenteritis in the HSCT cohort was the presence of endoscopic ulcers (OR 18.6, 95% CI 3.3 to 103.7) and >2 concurrent lines of treatment with immunosuppressive drugs. Antiviral therapy was administered in 70% of patients with IBD and 77% of HSCT patients with CMV disease. 71% of antiviral-treated patients with IBD showed an improvement of their disease activity and 14% underwent colectomy. The mortality rate of HSCT patients was 21% irrespective of their CMV status.

Conclusions: In addition to the implementation of histological methods, qPCR may be performed in patients with suspected high-risk IBD and HSCT patients for CMV colitis. Independent validations of these results in further prospective studies are needed.

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjgast-2018-000258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398871PMC
February 2019
3 Reads

Publication Analysis

Top Keywords

cmv colitis
20
hsct patients
20
risk factors
16
patients ibd
16
ibd hsct
12
factors cmv
12
predictors risk
12
patients
11
cmv
9
cmv disease
8
presence endoscopic
8
ibd cohort
8
ibd
8
treatment immunosuppressive
8
immunosuppressive drugs
8
lines treatment
8
concurrent lines
8
diagnostic accuracy
8
endoscopic ulcers
8
colitis ibd
8

Similar Publications